- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Shuttle Pharmaceuticals Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 27.02. | Shuttle Pharmaceuticals reports FY results | 1 | Seeking Alpha | ||
| 26.02. | Shuttle Pharma macht Fortschritte bei Glioblastom-Studie und erweitert Diagnostik | - | Investing.com Deutsch | ||
| 26.02. | Shuttle Pharma advances glioblastoma trial, expands diagnostics | 1 | Investing.com | ||
| 26.02. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate Update and Reports 2024 Results | 151 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical... ► Artikel lesen | |
| 26.02. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.02. | Shuttle Pharmaceuticals Holdings, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| SHUTTLE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.02. | Shuttle Pharmaceuticals Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 28.01. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma | 109 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused... ► Artikel lesen | |
| 21.01. | Shuttle Pharma hits 25% mark in glioblastoma trial | 1 | Investing.com | ||
| 21.01. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Shuttle Pharmaceuticals Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 07.01. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 07.01. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.24 | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program | 1 | GlobeNewswire (USA) | ||
| 19.12.24 | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.11.24 | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient | 116 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused... ► Artikel lesen | |
| 26.11.24 | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.24 | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Third Quarter 2024 Corporate Update | 127 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 0,130 | +1,17 % | Breaking News: Milliardärin investiert in InnoCan Pharma! | ||
| CRESCO LABS | 0,699 | +0,43 % | Cresco Labs Inc. to Report Fourth Quarter 2024 Financial Results on March 12, 2025 Business Wire | ||
| CSPC PHARMA | 0,590 | +2,22 % | CSPC Pharma's Earnings Hit By China's Drug Price Control Measures | ||
| TONIX PHARMACEUTICALS | 12,925 | -11,65 % | Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week | ||
| AMARIN | 0,480 | -2,04 % | Amarin Corporation plc: Amarin Marks Key Milestone for VASCEPA/VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol ... | -- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,800 | +0,63 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata | SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA... ► Artikel lesen | |
| JAGUAR HEALTH | 0,573 | -0,98 % | Jaguar Health, Inc.: Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value | Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,910 | +2,94 % | XORTX initiiert Gichtprogramm und NDA-Gespräche mit der FDA | - Typ-C-Meeting ist Voraussetzung für
die Einleitung eines verkürzten NDA-Zulassungsverfahrens für XRx-026 zur Gichtbehandlung
CALGARY, AB - 24. Februar 2025 / IRW-Press... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA LR23: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUMINUS WELLNESS... ► Artikel lesen | |
| CANNOVUM CANNABIS | 0,210 | -12,50 % | EQS-News: Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich | EQS-News: Cannovum Cannabis AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Sonstiges
Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich... ► Artikel lesen | |
| TALPHERA | 0,463 | -6,28 % | Talphera, Inc.: Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study | Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week
The FDA agreed to... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,064 | +6,72 % | BETTERLIFE HLDG (06909): FORM OF PROXY FOR USE AT EXTRAORDINARY GENERAL MEETING | ||
| MEDIPHARM LABS | 0,047 | -1,26 % | MediPharm to sell British Columbia cannabis facility to Rubicon for $4.5M | ||
| VIRACTA THERAPEUTICS | 0,010 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SCYNEXIS | 0,892 | +0,51 % | SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections | JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant... ► Artikel lesen |
Das Unternehmen SHUTTLE PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,466 Euro und damit -16,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHUTTLE PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
